![]() {[(4aR,6R,7R,7aR)-6-{6-Amino-8-[(4-chlorophenyl)sulfanyl]-9H-purin-9-yl}-7-methoxy-2-oxidotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-yl]oxy}methyl acetate structure
|
Common Name | {[(4aR,6R,7R,7aR)-6-{6-Amino-8-[(4-chlorophenyl)sulfanyl]-9H-purin-9-yl}-7-methoxy-2-oxidotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-yl]oxy}methyl acetate | ||
---|---|---|---|---|
CAS Number | 1152197-23-3 | Molecular Weight | 557.901 | |
Density | 1.8±0.1 g/cm3 | Boiling Point | 757.2±70.0 °C at 760 mmHg | |
Molecular Formula | C20H21ClN5O8PS | Melting Point | N/A | |
MSDS | N/A | Flash Point | 411.7±35.7 °C |
Use of {[(4aR,6R,7R,7aR)-6-{6-Amino-8-[(4-chlorophenyl)sulfanyl]-9H-purin-9-yl}-7-methoxy-2-oxidotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-yl]oxy}methyl acetate8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates Epac-Rap signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating Epac from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with PKA pathway[1][2]. |
Name | {[(4aR,6R,7R,7aR)-6-{6-Amino-8-[(4-chlorophenyl)sulfanyl]-9H-purin-9-yl}-7-methoxy-2-oxidotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-yl]oxy}methyl acetate |
---|---|
Synonym | More Synonyms |
Description | 8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates Epac-Rap signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating Epac from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with PKA pathway[1][2]. |
---|---|
Related Catalog | |
In Vitro | 8-pCPT-2'-O-Me-cAMP-AM (2.5 μM; 30 min) activates Epac and prevents adherens junction disassembly during hypoxia (60 min)[1]. 8-pCPT-2'-O-Me-cAMP-AM can cross the plasma membrane and is able to alter diverse cellular functions that include Rap1 GTPase activity, PKB, and ERK1/2 protein kinase activity, phospholipase C activity, Ca2+ signaling, ion channel activity, exocytosis, cell adhesion, and gene expression[2]. 8-pCPT-2'-O-Me-cAMP-AM stimulates insulin secretion with dose-dependent and glucose metabolism-dependent (0.1 or 1.11 mM) actions[2]. 8-pCPT-2'-O-Me-cAMP-AM (20 μM) activates the cAMP reporter Epac1-camps, while 8-pCPT-2'-O-Me-cAMP doesn’t in INS-1 cells[2]. 8-pCPT-2'-O-Me-cAMP-AM (0.3-3.0 μM; 0-300 sec) activates Epac1-camps in a dose- and time-dependent manner in high throughput assay[2]. |
In Vivo | 8-pCPT-2'-O-Me-cAMP-AM (intrarenal injection; ) activates renal Rap1 and likely is caused by activation of Epac in the tubular epithelium[1]. 8-pCPT-2'-O-Me-cAMP-AM preserves renal function by Epac activation and reduces tubular epithelial-cell stress during ischemia[1]. Animal Model: IR injuried mouse model[1] Dosage: 1.45 mM Administration: Intrarenal injection; mice were sacrificed at 24, 48, or 72 hours after ischemia Result: Protected renal injury during ischemia. |
References |
Density | 1.8±0.1 g/cm3 |
---|---|
Boiling Point | 757.2±70.0 °C at 760 mmHg |
Molecular Formula | C20H21ClN5O8PS |
Molecular Weight | 557.901 |
Flash Point | 411.7±35.7 °C |
Exact Mass | 557.053711 |
LogP | 2.51 |
Vapour Pressure | 0.0±2.5 mmHg at 25°C |
Index of Refraction | 1.750 |
Methanol, 1-[[(4aR,6R,7R,7aR)-6-[6-amino-8-[(4-chlorophenyl)thio]-9H-purin-9-yl]tetrahydro-7-methoxy-2-oxido-4H-furo[3,2-d]-1,3,2-dioxaphosphorin-2-yl]oxy]-, acetate (ester) |
{[(4aR,6R,7R,7aR)-6-{6-Amino-8-[(4-chlorophenyl)sulfanyl]-9H-purin-9-yl}-7-methoxy-2-oxidotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-yl]oxy}methyl acetate |